Author

M. Simuzingili

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

The Health and Economic Impact of the Adult-specific 21-valent (aPCV21) Pneumococcal Conjugate Vaccine vs PCV20 on Invasive Pneumococcal Disease Among Adults Aged 65 years in the United Kingdom: A Modeling Study

Introduction: This study compared the health and economic impact of the 21-valent pneumococcal conjugate vaccine (aPCV21) vs the 20-valent pneumococcal conjugate vaccine (PCV20) on invasive pneumococcal disease (IPD) and post-meningitis sequelae (PMS) among adults aged 65 years and older in the United Kingdom (UK). Met...

P. Mueller, M. Simuzingili, I. Matthews et al. · medRxiv · 0 citations

Open access Aug 2026

Evaluating the potential lifetime health and economic impact of PCV21, an adult-specific 21-valent pneumococcal conjugate vaccine, on invasive pneumococcal disease in adults aged ≥45 years in Spain.

In both age groups, PCV21 showed greater health and economic impact associated with IPD compared with PCV20, underscoring the potential benefits of incorporating PCV21 into adult pneumococcal vaccination strategies in Spain.

M. Simuzingili, Silvia Fernández-Soberón, Z. Yi et al. · Vaccine · 1 citation

Open access Aug 2026

The health and economic burden of invasive pneumococcal diseases attributable to PCV21 versus PCV20 serotypes among adults aged ≥ 45 years in Spain

The serotypes targeted by PCV21 impose a significantly higher health and economic burden of IPD in Spain relative to PCV20, and may help reduce the health and economic burden of IPD among Spanish adults, supporting its incorporation into national vaccination guidelines and adult immunization strategies.

M. Simuzingili, Silvia Fernández-Soberón, Z. Yi et al. · BMC Public Health · 0 citations